Table 6.
Everolimus therapy adherence and retention
| All patients (n = 116) | Children (n = 53) | Adults (n = 63) | p value | |
|---|---|---|---|---|
| Intake duration, daysa | ||||
| Mean ± SD | 1210 ± 991 | 949 ± 874 | 1424 ± 1035 | 0.049b |
| Median | 821 | 577 | 1111 | |
| Range | 1–3883 | 1–3103 | 89–3883 | |
| Retention rates, % (n)a | ||||
| First year (at 365 days) | 91.4 (106) | 88.7 (47) | 93.7 (59) | |
| Second year (at 730 days) | 84.5 (98) | 77.4 (41) | 90.5 (57) | |
| Third year (at 1095 days) | 82.8 (96) | 77.4 (41) | 87.3 (55) | |
EVE everolimus, SD standard deviation
aCalculated based on all patients with a defined starting and endpoint for EVE therapy or ongoing therapy
bCalculated using the log-rank test based on all patients with a defined starting and endpoint for EVE therapy or ongoing therapy